Action Inhibits mycobacterial cell wall synthesis and interferes with Metabolism . Well absorbed following oral and IM administration. Widely distributed to many body tissues and fluids. Readily crosses the blood-brain barrier . Crosses the placenta and enters breast milk in concentrations equal to plasma .
Remainder is excreted unchanged by the kidneys .
Hypersensitivity Acute liver disease Previous hepatitis from isoniazid. Nursing Implications Assessment Mycobacterial studies and susceptibility tests should be performed before and periodically throughout therapy to detect possible resistance . Patients over 50 yr are at highest risk. Available in tablet, syrup, and injectable forms. Medication may cause discomfort at injection site.